BR112013032871A8 - Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154 - Google Patents

Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154

Info

Publication number
BR112013032871A8
BR112013032871A8 BR112013032871A BR112013032871A BR112013032871A8 BR 112013032871 A8 BR112013032871 A8 BR 112013032871A8 BR 112013032871 A BR112013032871 A BR 112013032871A BR 112013032871 A BR112013032871 A BR 112013032871A BR 112013032871 A8 BR112013032871 A8 BR 112013032871A8
Authority
BR
Brazil
Prior art keywords
antigen
binding fragment
specifically binds
bacterial strain
strain expressing
Prior art date
Application number
BR112013032871A
Other languages
English (en)
Other versions
BR112013032871B1 (pt
BR112013032871A2 (pt
Inventor
Ellis Mark
Paul Humphreys David
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of BR112013032871A2 publication Critical patent/BR112013032871A2/pt
Publication of BR112013032871A8 publication Critical patent/BR112013032871A8/pt
Publication of BR112013032871B1 publication Critical patent/BR112013032871B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

CEPA HOSPEDEIRA BACTERIANA QUE EXPRESSA DSBC RECOMBINANTE. A presente invenção fornece uma célula bacteriana gram-negativa recombinante que compreende um vetor de expressão que compreende um polinucleotídeo recombinante que codifica DsbC e um ou mais polinucleotídeos que codificam um anticorpo ou um fragmento de ligação de antígeno deste que liga-se especificamente a CD154.
BR112013032871-1A 2011-07-13 2012-07-13 Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154 BR112013032871B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11173880 2011-07-13
EP11173880.3 2011-07-13
PCT/EP2012/002945 WO2013007388A1 (en) 2011-07-13 2012-07-13 Bacterial host strain expressing recombinant dsbc

Publications (3)

Publication Number Publication Date
BR112013032871A2 BR112013032871A2 (pt) 2017-01-24
BR112013032871A8 true BR112013032871A8 (pt) 2022-08-23
BR112013032871B1 BR112013032871B1 (pt) 2022-09-27

Family

ID=46545736

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013032871-1A BR112013032871B1 (pt) 2011-07-13 2012-07-13 Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154

Country Status (27)

Country Link
US (2) US9725516B2 (pt)
EP (2) EP3339325A1 (pt)
JP (3) JP6431370B2 (pt)
KR (1) KR102023786B1 (pt)
CN (1) CN103649124B (pt)
AU (1) AU2012283388B2 (pt)
BR (1) BR112013032871B1 (pt)
CA (1) CA2841824C (pt)
CY (1) CY1119985T1 (pt)
DK (1) DK2731973T3 (pt)
EA (1) EA031449B1 (pt)
ES (1) ES2659155T3 (pt)
HK (1) HK1194393A1 (pt)
HR (1) HRP20180226T1 (pt)
HU (1) HUE035674T2 (pt)
IL (1) IL229947B (pt)
IN (1) IN2014DN00202A (pt)
LT (1) LT2731973T (pt)
ME (1) ME02957B (pt)
MX (1) MX348738B (pt)
NO (1) NO2731973T3 (pt)
PL (1) PL2731973T3 (pt)
PT (1) PT2731973T (pt)
RS (1) RS56926B1 (pt)
SG (1) SG10201807560XA (pt)
SI (1) SI2731973T1 (pt)
WO (1) WO2013007388A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5721951B2 (ja) * 2007-03-22 2015-05-20 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用
AU2010299640B2 (en) 2009-09-24 2016-02-25 Ucb Pharma S.A. Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
EP3339325A1 (en) 2011-07-13 2018-06-27 UCB Biopharma SPRL Bacterial host strain expressing recombinant dsbc
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
HRP20231408T1 (hr) 2014-12-22 2024-02-16 UCB Biopharma SRL Proizvodnja proteina
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
JP6991978B2 (ja) 2016-01-27 2022-02-03 メディミューン，エルエルシー 定められるグリコシル化パターンを有する抗体を調製するための方法
JP2022506156A (ja) * 2018-11-05 2022-01-17 ジェネンテック， インコーポレイテッド 原核宿主細胞における２鎖タンパク質の産生方法
CN109371049A (zh) * 2018-11-14 2019-02-22 天津大学 分子伴侣在促进单克隆抗体的形成和/或提高单克隆抗体的表达量中的应用
JP2022525775A (ja) 2019-03-18 2022-05-19 バイオ－ラッド エービーディー セロテック ゲーエムベーハー ＳｐｙＴａｇ含有ペリプラズム融合タンパク質のプロテアーゼＴＳＰ及びＯＭＰＴ分解からの保護
EP4010500A1 (de) * 2019-08-05 2022-06-15 Wacker Chemie AG Bakterienstamm zur freisetzung eines rekombinanten proteins in einem fermentationsverfahren

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
AU4118393A (en) 1992-04-28 1993-11-29 Regents Of The University Of Michigan, The Human crabp-I and crabp-II
GB9215540D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US5304472A (en) 1992-11-20 1994-04-19 Genentech, Inc. Method of controlling polypeptide production in bacterial cells
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
JP2000083670A (ja) 1998-09-09 2000-03-28 Hsp Kenkyusho:Kk ＤｓｂＡ／ＤｓｂＢ／ＤｓｂＣ／ＤｓｂＤ発現プラスミド
US6306619B1 (en) 1999-06-29 2001-10-23 Washington University DegP periplasmic protease a new anti-infective target and an in vitro assay for DegP protease function
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
EP1314037A2 (en) 2000-09-01 2003-05-28 Biogen, Inc. Methods of designing and producing compounds having improved binding affinity for cd154 or other trimeric proteins
US7041479B2 (en) 2000-09-06 2006-05-09 The Board Of Trustess Of The Leland Stanford Junior University Enhanced in vitro synthesis of active proteins containing disulfide bonds
US6828121B2 (en) * 2000-12-14 2004-12-07 Genentech, Inc. Bacterial host strains
ATE405650T1 (de) * 2000-12-14 2008-09-15 Genentech Inc Produktion von ganzen antikörpern in prokaryontischen zellen
WO2004081026A2 (en) 2003-06-30 2004-09-23 Domantis Limited Polypeptides
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
WO2003018771A2 (en) 2001-08-27 2003-03-06 Genentech, Inc. A system for antibody expression and assembly
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
EA007905B1 (ru) 2001-11-16 2007-02-27 Байоджен Айдек Инк. Полицистронная экспрессия антител
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
EP1578447A4 (en) 2002-10-31 2009-06-03 Genentech Inc METHODS AND COMPOSITIONS THAT CAN INCREASE ANTIBODY PRODUCTION
AU2003285578B2 (en) 2002-12-03 2010-07-15 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
JP4667383B2 (ja) 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
JP4944608B2 (ja) 2003-07-26 2012-06-06 バイオジェン・アイデック・エムエイ・インコーポレイテッド 改良された抗原結合親和性を有する、変更された抗体
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
JP2008511337A (ja) * 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0425534D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
GB0520169D0 (en) 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
JP5721951B2 (ja) 2007-03-22 2015-05-20 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用
US8629246B2 (en) 2007-09-26 2014-01-14 Ucb Pharma S.A. Dual specificity antibody fusions
US7662587B1 (en) 2009-03-05 2010-02-16 E. I. Du Pont De Nemours And Company Gene knockout mutations that increase peptide production
AU2010299640B2 (en) * 2009-09-24 2016-02-25 Ucb Pharma S.A. Bacterial host strain
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
SI2496601T1 (sl) 2009-11-05 2017-09-29 F. Hoffmann-La Roche Ag Tehnike in sestavek za sekrecijo heterolognih polipeptidov
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
EP3339325A1 (en) 2011-07-13 2018-06-27 UCB Biopharma SPRL Bacterial host strain expressing recombinant dsbc
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product

Also Published As

Publication number Publication date
CA2841824A1 (en) 2013-01-17
US9957328B2 (en) 2018-05-01
MX348738B (es) 2017-06-27
HRP20180226T1 (hr) 2018-03-09
RS56926B1 (sr) 2018-05-31
PL2731973T3 (pl) 2018-04-30
US20170335003A1 (en) 2017-11-23
CN103649124B (zh) 2016-04-13
JP2020028299A (ja) 2020-02-27
WO2013007388A1 (en) 2013-01-17
KR20140039240A (ko) 2014-04-01
EA201490274A1 (ru) 2014-05-30
DK2731973T3 (da) 2018-01-29
HK1194393A1 (zh) 2014-10-17
MX2014000302A (es) 2014-02-17
JP2014521313A (ja) 2014-08-28
CA2841824C (en) 2021-07-13
BR112013032871B1 (pt) 2022-09-27
CY1119985T1 (el) 2018-12-12
AU2012283388B2 (en) 2017-04-20
IN2014DN00202A (pt) 2015-06-05
IL229947B (en) 2019-10-31
PT2731973T (pt) 2018-02-22
JP2018019719A (ja) 2018-02-08
EP2731973B1 (en) 2017-11-15
CN103649124A (zh) 2014-03-19
US9725516B2 (en) 2017-08-08
EP2731973A1 (en) 2014-05-21
LT2731973T (lt) 2018-02-26
JP7062626B2 (ja) 2022-05-17
NO2731973T3 (pt) 2018-04-14
KR102023786B1 (ko) 2019-09-20
EA031449B1 (ru) 2019-01-31
US20140141468A1 (en) 2014-05-22
EP3339325A1 (en) 2018-06-27
BR112013032871A2 (pt) 2017-01-24
HUE035674T2 (en) 2018-05-28
AU2012283388A1 (en) 2014-01-09
SI2731973T1 (en) 2018-04-30
SG10201807560XA (en) 2018-10-30
ME02957B (me) 2018-07-20
ES2659155T3 (es) 2018-03-14
JP6431370B2 (ja) 2018-11-28

Similar Documents

Publication Publication Date Title
BR112013032871A8 (pt) Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
CL2017001328A1 (es) Anticuerpos heterodimericos que unen cd3 y antígenos tumorales
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
CL2014001123A1 (es) Anticuerpos anti-il 36r; composicion farmaceutica que lo contiene; polinucleotido aislado que codifica el anticuerpo; metodo para la produccion del anticuerpo; kit de diagnostico que lo contiene.
BR112018001530A2 (pt) anticorpo biespecífico, polinucleotídeo, vetor, célula hospedeira, métodos para produzir o anticorpo biespecífico e de inibição do crescimento de células tumorais e composição farmacêutica
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
BR112017004614A2 (pt) terapias de combinação com anticorpos anti-cd38
BR112018006350A2 (pt) anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, formulação farmacêutica e uso do anticorpo
EP3702372A3 (en) Anti-cd40 human antibodies
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
CL2013003552A1 (es) Anticuerpo aislado que se une a la proteina 3 humana de tipo angiopoyetina (hangptl3); molécula de ácido nucleico; vector de expresión, célula hospedera; método de producción de un anticuerpo.
CL2012000524A1 (es) Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
BR112016014405A2 (pt) cepa mutante atenuada de salmonela
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
AR084234A1 (es) Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
UA117097C2 (uk) Антитіло проти лігандів рецептора в1 брадикініну
CR20150153A (es) Tratamiento para artitris reumatoide
BR112016024895A2 (pt) fator secretório de proteína com alta eficácia secretória e um vetor de expressão compreendendo o mesmo
BR112012010266A2 (pt) anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para preparar um anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, e para tratar um distúrbio inflamatório, e, uso de um anticorpo ou fragmento de ligação a fkn do mesmo
BR112014024269A8 (pt) Anticorpo ou um fragmento de ligação a antígeno do anticorpo, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento de ligação a antígeno, uso de uma composição, vetor, célula hospedeira transformada, e, método para produzir um anticorpo
BR112018073945A2 (pt) métodos para tratamento de miastenia grave generalizada refratária
WO2013115410A3 (en) Anti-phospholipase d4 antibody

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07K 16/28 , C12N 15/70

Ipc: C12N 1/21 (2006.01), C12N 15/70 (2006.01), C07K 16

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICACAO PARA CORRECAO DO TITULO.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/07/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.